Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Cote

Nurse Practitioner, Family Wichita, KS Nurse Practitioner

NPI 1801314745 CMS profile 10857007

1947 N Founders Cir, Wichita, KS 67206

Open in the dashboard

General payments

$7,156

124 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Cote of Wichita, KS is reported in the CMS Open Payments database as having received $7,156 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,402 22
2024 General $81 3
2023 General $1,108 29
2022 General $3,727 38
2021 General $838 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Cote
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Lauren Cote were reported at $1,402. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Lauren Cote Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $838 $124 $35–$379 $132
2022 $3,727 $141 $44–$430 $149
2023 $1,108 $154 $49–$476 $160
2024 $81 $165 $51–$504 $164
2025 $1,402 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Vertos Medical, Inc. $2,867 7 payments
  2. Relievant Medsystems, Inc. $2,084 11 payments
  3. Boston Scientific Corporation $1,305 16 payments
  4. Abbott Laboratories $876 89 payments
  5. SPR Therapeutics, Inc $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $2,725 4 payments
  2. Food and Beverage $1,726 110 payments
  3. Travel and Lodging $1,685 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,020 5 payments
Products named General payments · program years 2021–2025
  1. mild Device Kit $2,867 7 payments
  2. Intracept Pain $2,084 11 payments
  3. Intracept Pain $1,163 5 payments
  4. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $1,020 5 payments
  5. Intracept Pain $921 6 payments
  6. Intracept Pain $921 6 payments
  7. Intracept Pain $921 6 payments
  8. Proclaim IPG $192 19 payments
  9. PROCLAIM $187 25 payments
  10. Intracept Intracept Access Instruments - Additional VB (Gen 3)_NMOD $175 4 payments
  11. Other $566 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

269

Median for Nurse Practitioner: 389

Drug cost

$2,835

Median for Nurse Practitioner: $21,885

Branded share of claims

13.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 131 $1,210
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 36 $756
Pregabalin Generic 34 $404
Methylprednisolone Generic 28 $232
Baclofen Generic 17 $156
Tramadol Hcl Generic 11 $52
Meloxicam Generic 12 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$69,431

Of which drugs: $89

Medicare patients

419

Average age 74

Services billed

1,208

265 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Diabetes 31%
Depression 29%
Chronic kidney disease 25%
Atrial fibrillation 21%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 104 $87

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record